{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:30:57Z","timestamp":1762507857017,"version":"build-2065373602"},"reference-count":62,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"am","delay-in-days":362,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005617","name":"BHF Centre of Research Excellence, Oxford","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005617","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anaesthesia Critical Care & Pain Medicine"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.accpm.2019.09.009","type":"journal-article","created":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T14:06:08Z","timestamp":1570716368000},"page":"647-656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Update in antibiotic therapy in intensive care unit: report from the 2019 N\u00eemes International Symposium"],"prefix":"10.1016","volume":"38","author":[{"given":"Marc","family":"Leone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrien","family":"Bougl\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Philippe","family":"Lavigne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Neely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9-Artur","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Payen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Rello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Roger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredrik","family":"Sj\u00f6vall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.accpm.2019.09.009_bib0315","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","article-title":"Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016","volume":"43","author":"Rhodes","year":"2017","journal-title":"Intensive Care Med"},{"unstructured":"Tackling drug-resistant infections globally: Final report and recommendations, http:\/\/amr-review.org; 2016.[accessed 15\u00a0September 2019].","key":"10.1016\/j.accpm.2019.09.009_bib0320"},{"key":"10.1016\/j.accpm.2019.09.009_bib0325","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S1473-3099(16)30127-X","article-title":"Reflecting on the final report of the O\u2019Neill review on antimicrobial resistance","volume":"16","author":"Piddock","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.accpm.2019.09.009_bib0330","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.accpm.2019.09.009_bib0335","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3389\/fmicb.2019.00539","article-title":"Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: A review","volume":"10","author":"Mulani","year":"2019","journal-title":"Front Microbiol"},{"unstructured":"Annual surveillance reports on antimicrobial resistance. European Centre for Disease Prevention and Control, https:\/\/ecdc.europa.eu\/en\/antimicrobial-resistance\/surveillance-and-disease-data\/report; 2018.[accessed 15\u00a0September 2019].","key":"10.1016\/j.accpm.2019.09.009_bib0340"},{"key":"10.1016\/j.accpm.2019.09.009_bib0345","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.diagmicrobio.2013.10.002","article-title":"Molecular characteristics of carbapenemase-producing Enterobacteriaceae in China from 2008\u00a0to 2011: predominance of KPC-2\u00a0enzyme","volume":"78","author":"Li","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.accpm.2019.09.009_bib0350","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.molmed.2012.03.003","article-title":"Carbapenem resistance in Enterobacteriaceae: here is the storm!","volume":"18","author":"Nordmann","year":"2012","journal-title":"Trends Mol Med"},{"unstructured":"One Health Global Network. World Health Organisation, http:\/\/www.onehealthglobal.net; 2019 [accessed 15\u00a0September 2019]","key":"10.1016\/j.accpm.2019.09.009_bib0355"},{"key":"10.1016\/j.accpm.2019.09.009_bib0360","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.cmi.2018.04.004","article-title":"Carbapenem-resistant Enterobacteriaceae in wildlife, food-producing, and companion animals: a systematic review","volume":"24","author":"K\u00f6ck","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.accpm.2019.09.009_bib0365","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.chest.2019.01.013","article-title":"Principles and Practice of Antibiotic Stewardship in the ICU","volume":"156","author":"Pickens","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.accpm.2019.09.009_bib0370","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s00134-019-05520-5","article-title":"Rationalizing antimicrobial therapy in the ICU: a narrative review","volume":"45","author":"Timsit","year":"2019","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.accpm.2019.09.009_bib0375","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/jac\/dkz113","article-title":"Implementation of antibiotic stewardship programmes in French ICUs in 2018: a nationwide cross-sectional survey","volume":"74","author":"Delannoy","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.accpm.2019.09.009_bib0380","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s13054-015-1000-z","article-title":"Adequate antibiotic therapy prior to ICU admission in patients with severe sepsis and septic shock reduces hospital mortality","volume":"19","author":"Garnacho-Montero","year":"2015","journal-title":"Crit Care"},{"key":"10.1016\/j.accpm.2019.09.009_bib0385","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1097\/CCM.0b013e3181eb3ccd","article-title":"Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis","volume":"38","author":"Kumar","year":"2010","journal-title":"Crit Care Med"},{"key":"10.1016\/j.accpm.2019.09.009_bib0390","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/CCM.0b013e31822b50c2","article-title":"Survival in neutropenic patients with severe sepsis or septic shock","volume":"40","author":"Legrand","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1016\/j.accpm.2019.09.009_bib0395","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1001\/jama.2012.5833","article-title":"Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial","volume":"307","author":"Brunkhorst","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.accpm.2019.09.009_bib0400","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jinf.2016.11.013","article-title":"Empirical mono- versus combination antibiotic therapy in adult intensive care patients with severe sepsis\u2013A systematic review with meta-analysis and trial sequential analysis","volume":"74","author":"Sj\u00f6vall","year":"2017","journal-title":"J Infect"},{"key":"10.1016\/j.accpm.2019.09.009_bib0405","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/cid\/cix186","article-title":"Short-course adjunctive gentamicin as empirical therapy in patients with severe sepsis and septic shock: a prospective observational cohort study","volume":"64","author":"Ong","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.accpm.2019.09.009_bib0410","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ajic.2018.09.010","article-title":"Impact of an Acinetobacter baumannii outbreak on kidney events in a burn unit: a targeted machine learning analysis","volume":"47","author":"Vauchel","year":"2019","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.accpm.2019.09.009_bib0415","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s15010-013-0460-9","article-title":"Development of acute kidney injury during continuous infusion of vancomycin in septic patients","volume":"41","author":"Cianferoni","year":"2013","journal-title":"Infection"},{"key":"10.1016\/j.accpm.2019.09.009_bib0420","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s00134-009-1730-y","article-title":"Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia","volume":"36","author":"Martin-Loeches","year":"2010","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.accpm.2019.09.009_bib0425","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1183\/09031936.00054108","article-title":"Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia","volume":"33","author":"Restrepo","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.accpm.2019.09.009_bib0430","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/cid\/civ1199","article-title":"A systematic review of the definitions determinants, and clinical outcomes of antimicrobial de-escalation in the intensive care unit","volume":"62","author":"Tabah","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.accpm.2019.09.009_bib0435","first-page":"649","article-title":"Elaboration of a consensual definition of de-escalation allowing a ranking of \u03b2-lactams","volume":"21","author":"Weiss","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.accpm.2019.09.009_bib0440","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1086\/677633","article-title":"Development of an antibiotic spectrum score based on veterans affairs culture and susceptibility data for the purpose of measuring antibiotic de-escalation: a modified Delphi approach","volume":"35","author":"Madaras-Kelly","year":"2014","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.accpm.2019.09.009_bib0445","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1186\/cc10072","article-title":"Impact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia","volume":"15","author":"Joung","year":"2011","journal-title":"Crit Care"},{"key":"10.1016\/j.accpm.2019.09.009_bib0450","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00134-014-3411-8","article-title":"De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial","volume":"40","author":"Leone","year":"2014","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.accpm.2019.09.009_bib0455","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/cc11197","article-title":"Early use of imipenem\/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial","volume":"16","author":"Kim","year":"2012","journal-title":"Crit Care"},{"key":"10.1016\/j.accpm.2019.09.009_bib0460","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00134-016-4301-z","article-title":"Impact of de-escalation of beta-lactam antibiotics on the emergence of antibiotic resistance in ICU patients: a retrospective observational study","volume":"42","author":"De Bus","year":"2016","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.accpm.2019.09.009_bib0465","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.accpm.2019.09.009_bib0470","doi-asserted-by":"crossref","first-page":"e02042","DOI":"10.1128\/AAC.02042-17","article-title":"prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.accpm.2019.09.009_bib0475","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.addr.2014.05.016","article-title":"Innovative approaches to optimizing the delivery of vancomycin in individual patients","volume":"77","author":"Pai","year":"2014","journal-title":"Adv Drug Del Rev"},{"key":"10.1016\/j.accpm.2019.09.009_bib0480","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","article-title":"Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R","volume":"34","author":"Neely","year":"2012","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.accpm.2019.09.009_bib0485","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1093\/jac\/dkx209","article-title":"Too much of a good thing: a retrospective study of beta-lactam concentration-toxicity relationships","volume":"72","author":"Imani","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.accpm.2019.09.009_bib0490","first-page":"497","article-title":"Elevated beta-lactam concentrations associated with neurological deterioration in ICU septic patients","volume":"81","author":"Beumier","year":"2015","journal-title":"Minerva Anestesiol"},{"key":"10.1016\/j.accpm.2019.09.009_bib0495","doi-asserted-by":"crossref","first-page":"R264","DOI":"10.1186\/cc13094","article-title":"Cefepime neurotoxicity in the intensive care unit: a cause of severe, underappreciated encephalopathy","volume":"17","author":"Fugate","year":"2013","journal-title":"Crit Care"},{"key":"10.1016\/j.accpm.2019.09.009_bib0500","article-title":"Cefepime neurotoxicity: thresholds and risk factors. A retrospective cohort study","author":"Boschung-Pasquier","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.accpm.2019.09.009_bib0505","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1053\/j.ajkd.2014.04.027","article-title":"Biopsy-proven acute interstitial nephritis, 1993-2011: a case series","volume":"64","author":"Muriithi","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.accpm.2019.09.009_bib0510","first-page":"62","article-title":"Incidence of acute kidney injury among patients treated with piperacillin-tazobactam or meropenem in combination with vancomycin","author":"Rutter","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.accpm.2019.09.009_bib0515","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.accpm.2019.09.009_bib0520","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/jac\/dkv491","article-title":"A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study","volume":"71","author":"Brasseur","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.accpm.2019.09.009_bib0525","article-title":"Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study","volume":"360","author":"Pasternak","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.accpm.2019.09.009_bib0530","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.mito.2013.10.005","article-title":"Side effects of antibiotics during bacterial infection: mitochondria, the main target in host cell","volume":"16","author":"Singh","year":"2014","journal-title":"Mitochondrion"},{"key":"10.1016\/j.accpm.2019.09.009_bib0535","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1126\/scitranslmed.3006055","article-title":"Bactericidal antibiotics induce mitochondrial dysfunction and oxidative damage in Mammalian cells","volume":"5","author":"Kalghatgi","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.accpm.2019.09.009_bib0540","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.cmi.2015.12.016","article-title":"Global survey on nebulization of antimicrobial agents in mechanically ventilated patients: a call for international guidelines","volume":"22","author":"Sol\u00e9-Lleonart","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.accpm.2019.09.009_bib0545","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.4187\/respcare.04519","article-title":"intratracheal administration of antimicrobial agents in mechanically ventilated adults: an international survey on delivery practices and safety","volume":"61","author":"Sol\u00e9-Lleonart","year":"2016","journal-title":"Respir Care"},{"key":"10.1016\/j.accpm.2019.09.009_bib0550","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/ALN.0000000000001570","article-title":"Nebulization of antiinfective agents in invasively mechanically ventilated adults: a systematic review and meta-analysis","volume":"126","author":"Sol\u00e9-Lleonart","year":"2017","journal-title":"Anesthesiology"},{"key":"10.1016\/j.accpm.2019.09.009_bib0555","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cmi.2017.04.011","article-title":"Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases","volume":"23","author":"Rello","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.accpm.2019.09.009_bib0560","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.cmi.2017.03.018","article-title":"Key considerations on nebulization of antimicrobial agents to mechanically ventilated patients","volume":"23","author":"Rello","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.accpm.2019.09.009_bib0565","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/MAT.0000000000000475","article-title":"Extracorporeal Life Support Organization Registry International Report 2016","volume":"63","author":"Thiagarajan","year":"2017","journal-title":"ASAIO J"},{"key":"10.1016\/j.accpm.2019.09.009_bib0570","doi-asserted-by":"crossref","first-page":"e01949","DOI":"10.1371\/journal.pone.0194976","article-title":"Ventilator-associated pneumonia in patients assisted by veno-arterial extracorporeal membrane oxygenation support: epidemiology and risk factors of treatment failure","volume":"13","author":"Bougl\u00e9","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.accpm.2019.09.009_bib0575","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.clinthera.2016.07.169","article-title":"Pharmacokinetics and dosing of anti-infective drugs in patients on extracorporeal membrane oxygenation: a review of the current literature","volume":"38","author":"Sherwin","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.accpm.2019.09.009_bib0580","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13054-018-2122-x","article-title":"Predictors of insufficient peak amikacin concentration in critically ill patients on extracorporeal membrane oxygenation","volume":"22","author":"Touchard","year":"2018","journal-title":"Crit Care"},{"key":"10.1016\/j.accpm.2019.09.009_bib0585","article-title":"PHARMECMO: Therapeutic drug monitoring and adequacy of current dosing regimens of antibiotics in patients on Extracorporeal Life Support","author":"Bougl\u00e9","year":"2019","journal-title":"Anaesth Crit Care Pain Med"},{"key":"10.1016\/j.accpm.2019.09.009_bib0590","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13054-016-1197-5","article-title":"Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?","volume":"20","author":"Bassetti","year":"2016","journal-title":"Crit Care"},{"key":"10.1016\/j.accpm.2019.09.009_bib0595","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1007\/s00134-017-4878-x","article-title":"Antimicrobial resistance in the next 30\u00a0years, humankind, bugs and drugs: a visionary approach","volume":"43","author":"Bassetti","year":"2017","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.accpm.2019.09.009_bib0600","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciy576","article-title":"Ceftazidime\/avibactam Meropenem\/vaborbactam or both?. Clinical and formulary considerations","volume":"68","author":"Pogue","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.accpm.2019.09.009_bib0605","first-page":"385","article-title":"Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug- resistant\/extensively drug-resistant\/pandrug-resistant bacteria","volume":"24","author":"Bassetti","year":"2018","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.accpm.2019.09.009_bib0610","first-page":"61","article-title":"Emergence of ceftazidime-avibactam resistance due to plasmid-borne blakpc-3\u00a0mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.accpm.2019.09.009_bib0615","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fmed.2019.00074","article-title":"Treatment of infections due to MDR gram-negative bacteria","volume":"6","author":"Bassetti","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.accpm.2019.09.009_bib0620","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, pahse 3, non-inferiority trial","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"}],"container-title":["Anaesthesia Critical Care & Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352556819304278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352556819304278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:43:55Z","timestamp":1762479835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352556819304278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S2352556819304278"],"URL":"https:\/\/doi.org\/10.1016\/j.accpm.2019.09.009","relation":{},"ISSN":["2352-5568"],"issn-type":[{"type":"print","value":"2352-5568"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update in antibiotic therapy in intensive care unit: report from the 2019 N\u00eemes International Symposium","name":"articletitle","label":"Article Title"},{"value":"Anaesthesia Critical Care & Pain Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.accpm.2019.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise d'anesth\u00e9sie et de r\u00e9animation (Sfar).","name":"copyright","label":"Copyright"}]}}